1. Background
2. Objectives
3. Patients and Methods
3.1. Ethics Approval
3.2. Statistical Analysis
4. Results
| Etiology of Liver Transplant | No. (%) |
|---|---|
| Congenital Metabolic Disorder | |
| Wilson’s Disease | 56 (14.3) |
| Tyrosinaemia | 43 (11) |
| Crigler Najar(type1) | 30 (7.7) |
| Familial Hypercholesterolemia | 19 (4.8) |
| α1-anti Trypsin Deficiency | 1 (0.2) |
| Total | 149 (38) |
| Cholestatic Disease | |
| Biliary Atresia | 56 (14.3) |
| PFICa | 47 (12) |
| PSC | 10 (2.6) |
| Neonatal Hepatitis | 10 (2.6) |
| Caroli Disease | 5 (1.3) |
| Intrahepatic Bile Duct Paucity | 2 (0.5) |
| Total | 130 (33.3) |
| Hepatitis | |
| Autoimmune Hepatitis | 47 (10.7) |
| Hepatitis B | 4 (1) |
| Hepatitis C | 1 (0.2) |
| Total | 47 (11.9) |
| Malignancy,Hepatocellular Carcinoma | 4 (1) |
| Other | |
| Cryptogenic cirrhosis | 56 (14.3) |
| Fibro Polycystic Liver Disease | 4 (1) |
| Budd-Chiari Syndrome | 2 (0.5) |
| Total | 62 (15.8) |
| Total | 392 (100) |
a Abbreviations: PSC, Primary sclerosing cholangitis; PFIC, Progressive familial intrahepatic cholestasis
| Cumulative Survival, % | |||||||
|---|---|---|---|---|---|---|---|
| Category | 1-Month | 3-Months | 6-Months | 1-Year | 3-Years | 5-years | 10-Years |
| All patients | 86 | 82 | 78 | 73 | 67 | 66 | 66 |
| Patients Who Survived at Least 1 Month After the Transplantation | 96 | 92 | 89 | 84 | 78 | 77 | 77 |
| Patients Who Survived at Least 3 Months after the Transplantation | 96 | 95 | 92 | 89 | 82 | 81 | 81 |
| Metabolic Disease | Cholestatic Disease | Hepatitis Disease | Malignancy Disease | Other Disease | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SRb, % | SEa | SRb, % | SEa | SRb, % | SEa | SRb, % | SEa | SRb, % | SEa | |
| 1 year | 77 | 0.13 | 61 | 0.07 | 78 | 0.23 | 56 | 0.29 | 81 | 0.23 |
| 2 years | 76 | 0.77 | 60 | 0.59 | 78 | 0.32 | 56 | 0.41 | 74 | 0.46 |
| 3 years | 69 | 0.77 | 57 | 0.69 | 74 | 0.79 | 56 | 0.51 | 74 | 0.62 |
| 4 years | 67 | 0.99 | 57 | 0.79 | 74 | 1.07 | 56 | 0.59 | 74 | 0.74 |
| 5 years | 67 | 1.19 | 57 | 0.88 | 74 | 1.3 | - | - | 74 | 0.84 |
| 6 years | 67 | 1.36 | 57 | 0.97 | 74 | 1.49 | - | - | 74 | 0.94 |
aStandard error of survival rate
bSurvival rate
| Weight, > 1 SD Above Mean | Weight, 0-1 SD Above Mean | Weight, 0-1 SD Below Mean | Weight, > 1 SD Below Mean | |||||
|---|---|---|---|---|---|---|---|---|
| SRb, % | SEa | SRb, % | SEa | SRb, % | SEa | SRb, % | SEa | |
| 1, year | 78 | 0.22 | 79 | 0.20 | 68 | 0.58 | 29 | 0.04 |
| 2, years | 78 | 0.31 | 73 | 0.53 | 65 | 0.38 | 29 | 0.06 |
| 3, years | 75 | 0.79 | 69 | 0.84 | 61 | 0.49 | 14 | 0.08 |
| 4, years | 68 | 0.97 | 69 | 1.08 | 61 | 0.60 | 14 | 0.1 |
| 5, years | 68 | 1.17 | 69 | 1.27 | 61 | 0.69 | - | - |
| 6, years | 68 | 1.34 | 69 | 1.44 | 61 | 0.77 | - | - |
aStandard error of survival rate
bSurvival Rate
| HRa | P value | 95%CI for HR | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Graft type | ||||
| Whole | 1 | |||
| Partial | 3.36 | 0.01 | 1.32 | 8.5 |
| Split | 5.1 | 0.007 | 1.57 | 16.5 |
| PELD/MELD | ||||
| < 20 | 1 | |||
| ≥ 20 | 2.34 | 0.02 | 1.09 | 5.04 |
| Complication | ||||
| No | 1 | |||
| Yes | 2.56 | 0.01 | 1.2 | 5.4 |
| Initial diagnosis | ||||
| Metabolic Disease | 1 | |||
| Cholestatic | 2.1 | 0.06 | 0.94 | 4.9 |
| Hepatitis | 0.8 | 0.7 | 0.21 | 3.07 |
| Other | 0.34 | 0.1 | 0.07 | 1.6 |
aHazard ratio





![Investigation of the of the Proportional Hazard Assumption Based on the Type of Graft Using the Scatter Plot of [Log (-Log) (t)] on Log (t) Investigation of the of the Proportional Hazard Assumption Based on the Type of Graft Using the Scatter Plot of [Log (-Log) (t)] on Log (t)](https://brieflands.com/journals/hepatmon/articles/15269/figures/hepatmon-13-07-10257-i006-preview.webp)